Vivo Capital’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,393,432
| Closed | -$149M | – | 54 |
|
|
2025
Q3 | $149M | Hold |
1,393,432
| – | – | 11.97% | 2 |
|
|
2025
Q2 | $132M | Sell |
1,393,432
-45,353
| -3% | -$3.36M | 13.49% | 2 |
|
|
2025
Q1 | $91.3M | Sell |
1,438,785
-845,190
| -37% | -$50.6M | 12.1% | 2 |
|
|
2024
Q4 | $106M | Sell |
2,283,975
-1,265,783
| -36% | -$47.5M | 11.88% | 2 |
|
|
2024
Q3 | $102M | Hold |
3,549,758
| – | – | 8.45% | 4 |
|
|
2024
Q2 | $51.3M | Sell |
3,549,758
-60,419
| -2% | -$882K | 4.74% | 7 |
|
|
2024
Q1 | $58.1M | Sell |
3,610,177
-639,741
| -15% | -$11.1M | 4.56% | 6 |
|
|
2023
Q4 | $84.5M | Hold |
4,249,918
| – | – | 6.92% | 3 |
|
|
2023
Q3 | $69.3M | Hold |
4,249,918
| – | – | 7.59% | 4 |
|
|
2023
Q2 | $89.8M | Hold |
4,249,918
| – | – | 6.2% | 3 |
|
|
2023
Q1 | $85.3M | Hold |
4,249,918
| – | – | 5.92% | 3 |
|
|
2022
Q4 | $3.64M | Hold |
4,249,918
| – | – | 0.42% | 38 |
|
|
2022
Q3 | $43.4M | Buy |
4,249,918
+1,500,000
| +55% | +$12.6M | 4.8% | 4 |
|
|
2022
Q2 | $11.5M | Hold |
2,749,918
| – | – | 1.16% | 23 |
|
|
2022
Q1 | $13.7M | Hold |
2,749,918
| – | – | 0.94% | 25 |
|
|
2021
Q4 | $18.5M | Hold |
2,749,918
| – | – | 1.11% | 24 |
|
|
2021
Q3 | $15.1M | Sell |
2,749,918
-298,589
| -10% | -$1.74M | 0.68% | 28 |
|
|
2021
Q2 | $19.9M | Hold |
3,048,507
| – | – | 0.86% | 25 |
|
|
2021
Q1 | $25.5M | Hold |
3,048,507
| – | – | 0.9% | 24 |
|
|
2020
Q4 | $21.3M | Hold |
3,048,507
| – | – | 0.95% | 25 |
|
|
2020
Q3 | $19M | Buy |
3,048,507
+1,555,556
| +104% | +$10.7M | 1.1% | 23 |
|
|
2020
Q2 | $6.99M | Hold |
1,492,951
| – | – | 0.5% | 40 |
|
|
2020
Q1 | $6.15M | Buy |
+1,492,951
| New | +$8.19M | 0.56% | 40 |
|
|
2019
Q3 | – | Sell |
-1,492,951
| Closed | -$7.61M | – | 27 |
|
|
2019
Q2 | $7.61M | Hold |
1,492,951
| – | – | 0.71% | 30 |
|
|
2019
Q1 | $9.7M | Hold |
1,492,951
| – | – | 0.97% | 27 |
|
|
2018
Q4 | $13.4M | Hold |
1,492,951
| – | – | 1.72% | 16 |
|
|
2018
Q3 | $18.7M | Hold |
1,492,951
| – | – | 1.88% | 17 |
|
|
2018
Q2 | $2.79M | Hold |
1,492,951
| – | – | 0.36% | 34 |
|
|
2018
Q1 | $29.9M | Hold |
1,492,951
| – | – | 4.23% | 6 |
|
|
2017
Q4 | $17.7M | Hold |
1,492,951
| – | – | 3.8% | 12 |
|
|
2017
Q3 | $22.9M | Buy |
1,492,951
+788,726
| +112% | +$10.4M | 4.63% | 6 |
|
|
2017
Q2 | $8.21M | Buy |
+704,225
| New | +$9.33M | 2.07% | 11 |
|
Other funds holding VRNA
Vivo Capital's VRNA Position: Q4 2025 in Review
Vivo Capital sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,393,432 shares — an estimated $149M sold.
Vivo Capital first reported a position in VRNA in Q2 2017 and held it in 32 quarters. The position peaked at $149M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Vivo Capital reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Vivo Capital sold 1,393,432 Verona Pharma shares in Q4 2025, an estimated $149M.
- Vivo Capital first reported a position in Verona Pharma in Q2 2017 and held it in 32 quarters.
- Vivo Capital's Verona Pharma position peaked at $149M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Vivo Capital's 13F filing for Q4 2025, filed 13 Feb 2026.